Top Markets
Coin of the day
Acrivon Therapeutics, Inc. Common Stock Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock

ACRV
Classement en actions #22054
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Prix de l'action
$2.23
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$95.23M
Changement (1 jour)
1.14%
Changement (1 an)
63.60%
Pays
US
Échange Acrivon Therapeutics, Inc. Common Stock (ACRV)

Catégorie

EPS pour Acrivon Therapeutics, Inc. Common Stock (ACRV)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Acrivon Therapeutics, Inc. Common Stock, l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Acrivon Therapeutics, Inc. Common Stock de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH